News

Swiss biopharmaceutical company Basilea Pharmaceutica has reported that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, has obtained

US-based healthcare company Myriad Genetics has reported a net profit of $25.31m, or $0.25 per diluted share for the third quarter of fiscal 2009, compared to a net

Novavax, a biotechnology company, has reported vaccination of healthy volunteers in the second clinical trial of its virus-like particle or VLP seasonal influenza vaccine. Building on data from

NiTi Surgical Solutions, a surgical device company, has launched the ColonRing, its new closure technology for colorectal surgery, in the US. The current surgical standard for reconnecting the

Calistoga Pharmaceuticals, a developer of medicines for the treatment of cancer and inflammatory diseases, has closed a $30m series B financing.Investors participating in the financing include Alta Partners,

Teva Pharmaceutical Industries, an Israeli pharmaceutical company, has reported a net income of $451m, or $0.51 diluted earnings per share, for the first quarter of 2009 compared to

Rexahn Pharmaceuticals, a biopharmaceutical company, has reported preliminary results for its sexual dysfunction drug candidate, Zoraxel, from a Phase IIa clinical study for the treatment of erectile dysfunction.

Indian pharmaceutical company Jubilant Organosys has reported that its subsidiary in the US, Draximage has received FDA approval for the company’s abbreviated new drug application for generic Sestamibi.

Eclipsys, a provider of clinical, revenue cycle and performance management software, has released an influenza A H1N1 Outcomes Toolkit designed to help limit the spread of the H1N1